Advertisement

Topics

Search Results for "Galderma Company Rpofile"

14:49 EDT 25th May 2016 | BioPortfolio

Matching Channels

Medtronic

With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

MediciGlobal is a specialty patient recruitment-retention organization serving the clinical trials industry

MediciGlobal is a specialty patient recruitment-retention organization serving the clinical trials industry. For more than two decades, the company has led the industry in developing innovative p...

Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Galderma unveils a new look for Cetaphil line

One of Galderma's most popular skin care product lines is getting a full graphics and packaging upgrade. read more

Galderma launches new Mirvaso Gel pump dispenser

David SalazarMirvaso was approved in 2013 as a first-in-class treatment for rosacea-related redness, and according to Galderma it can start working for some patients 30 minutes after application and l...

FDA Mulls Approach To Switches In Context Of Galderma's Acne Drug OTC Bid

FDA's OTC division uses the NDAC meeting on Galderma's Differin Gel switch proposal to ask for the advisory committee's input on evaluating future NDAs for other switches that could introduce new risk...

Galderma Acne Ingredient Rx-to-OTC Switch Headed For NDAC In April

FDA schedules an April 15 NDAC meeting to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.

Galderma Acne Ingredient Switch Receives NDAC Review In April

FDA schedules an April 15 NDAC to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.

Galderma adds new president, general manager of North American business

David SalazarMiles Harrison joined Galderma U.S. in 2014 from Novartis as VP and general manager, self-medication business unit, which includes Cetaphil.  read more

NDAC Support For Galderma's Acne Drug OTC Approval Comes With Advice On Evaluating Switches

FDA's OTC division uses the NDAC meeting on Galderma's Differin Gel switch proposal to ask for input on evaluating future NDAs for other switches that would introduce new risks to the OTC space.

Ipsen and Galderma Expand Current Distribution Agreement for Dysport in Aesthetic Indications to Some Key Asia-Pacific Territories1

Ipsen acquires the intellectual property for Galderma's liquid toxin in some key Asia-Pacific territories (APAC1 Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharm...

Matching PubMed Articles

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement